NRG-GU009, also known as the “PREDICT-RT” trial, is a clinical study for people with high-risk prostate cancer that will be analyzing your prostate tumor tissue from your biopsy to test for different genes that predict the risk of your cancer spreading. This is called the Decipher risk score. If you have a lower-risk score, you will be assigned to the part of the study comparing a less aggressive treatment to the usual treatment. If you have a higher-risk score or if your disease had spread to your pelvic lymph nodes, you will be assigned to the part of the study comparing a more aggressive treatment to the usual treatment for this type of cancer.
Researchers are performing this study to see if a shorter hormone therapy treatment schedule is as effective as the usual hormone therapy treatment schedule at controlling cancer for high-risk prostate cancer patients with a lower gene risk score. Additionally, researchers want to know if adding a new hormone therapy drug to the usual treatment can increase the length of time without prostate cancer returning for high-risk prostate cancer patients with a higher gene risk score.
More information about this particular study is located on ClinicalTrials.gov
If you are over 18 with high-risk prostate cancer, you may be able to participate. Your healthcare team is the best source for information about your treatment options, including cancer clinical trials. Be sure to take this information to your doctor to discuss your questions and concerns in general and specific to the PREDICT-RT study.
Are you interested in joining the study? Find a participating location
Additional information for the PREDICT-RT study can be found in the Patient Study Brochure. Download Brochure
Below, you can find FAQs about clinical research and this particular clinical trial.
Talk to your insurance provider and make sure that you understand what your insurance pays for and what it doesn’t pay for if you take part in this clinical trial. Also, find out if you need approval from your plan before you can take part in the study.
You will not be paid for taking part in this study.
Doctors and researchers conduct a clinical study, also called a “clinical trial,” to find better ways to prevent, diagnose, or treat an illness. NRG Oncology is supported by the National Cancer Institute (NCI) and runs clinical studies specifically for patients with cancer or to prevent cancer. Most clinical studies test something we know against something we don’t know. In all situations, these studies are strictly evaluated before they are allowed to be offered to any patient. The study is designed to answer the question that we do not know the answer to, so that current and future patients may have better treatments or information than what we currently have. There are different types of clinical studies that might be available for patients. For more information see “Types of Clinical Trials” and “Phases of Clinical Trials”.
Patients who volunteer to take part in a clinical study are followed closely by their health care professionals and members of the research team. For more information see “Research Team Members”.
At NRG Oncology, we focus on conducting clinical studies aimed to improve current cancer care practices and the lives of cancer patients. NRG Oncology partners with more than 1,300 member sites world-wide to research ways to improve treatment standards in the cancer community. Our organization is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trial's Network.